RecruitingRespiratory Syncytial Virus Infections
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
Sponsor: GlaxoSmithKline
You may qualify if…
- ✓ Participants of the RSV OA=ADJ-023 study from the Per Protocol Set (Visit 3 for participants in IC\_1 and Visit 4 for participants in IC\_2 group), who received either 1 or 2 doses of the adjuvanted RSVPreF3 vaccine and for whom the immunogenicity data are available.
- ✓ Participants who, can and will comply with the requirements of the protocol (e.g., completion of the paper diary cards (as applicable), return for follow-up visits, ability to access and utilize a phone or other electronic communications, have regular contact to allow evaluation during the study).
- ✓ Written or witnessed informed consent obtained from the participant prior to performance of any study-specific procedure.
- ✓ Female participants of nonchildbearing potential may be enrolled in the study. Non childbearing potential is defined as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, and post-menopause.
- ✓ Female participants of childbearing potential may be enrolled in the study if the participant:
- ✓ has practiced adequate contraception from 1 month prior to study intervention administration, and
- ✓ agreed to continue adequate contraception until 1 month after study intervention, and
- ✓ has a negative pregnancy test on the day of and prior to study intervention administration.
You may not qualify if…
- ✕ Medical conditions
- ✕ Any history of dementia or any medical condition that moderately or severely impairs cognition.
- ✕ Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival up to study end).
- ✕ History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention
- ✕ Acute or chronic clinically significant cardiovascular or hepatic functional abnormality, as determined by physical examination or laboratory screening tests.
- ✕ Recurrent or uncontrolled neurological disorders or seizures. Participants with medically controlled chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
- ✕ Any condition which, in the judgment of the investigator, would make IM injection unsafe.
- ✕ Any other clinical condition that might pose additional risk to the participant due to participation in the clinical study.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07092865 · last updated 2026-03-06